The POTCAST trial shows raising plasma potassium to high-normal levels reduces ventricular arrhythmia risk, hospitalisations, and death in ICD patients. The post ESC 2025: Raising Potassium Reduces Ventricular Arrhythmia Risk in High-Risk Patients appeared first on European Medical Journal.
